Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Curcumagalactomannoside** is a proprietary, food-grade curcumin formulation marketed as **CurQfen**. It is a water-dispersible, non-covalent complex of turmeric-derived curcuminoids with a fenugreek galactomannan dietary-fiber matrix, designed to increase systemic exposure to unconjugated free curcuminoids relative to conventional curcumin preparations. It was originated by Akay and is sold as a nutraceutical ingredient for oral dietary-supplement products. Human studies have evaluated it for knee osteoarthritis, occupational stress-related symptoms, safety, bioavailability, and other wellness-related outcomes; a six-week active-controlled knee-osteoarthritis study reported improvements in pain and function. In vitro, CGM induced ROS-associated mitochondrial apoptosis in HeLa cervical-cancer cells, but it is not an approved oncology therapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27043120/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumagalactomannoside.